Molecular pathology of emerging coronavirus infections
Identifieur interne : 001968 ( Main/Exploration ); précédent : 001967; suivant : 001969Molecular pathology of emerging coronavirus infections
Auteurs : Lisa E. Gralinski [États-Unis] ; Ralph S. Baric [États-Unis]Source :
- The Journal of Pathology [ 0022-3417 ] ; 2015-01.
Descripteurs français
- KwdFr :
- Anatomopathologie moléculaire (), Animaux, Antiviraux (usage thérapeutique), Appareil respiratoire (), Appareil respiratoire (anatomopathologie), Appareil respiratoire (immunologie), Appareil respiratoire (virologie), Biopsie, Coronavirus (), Coronavirus (immunologie), Coronavirus (isolement et purification), Coronavirus (pathogénicité), Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification), Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité), Facteurs de risque, Humains, Immunité innée, Infections à coronavirus (anatomopathologie), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Interactions hôte-pathogène, Maladies transmissibles émergentes, Syndrome respiratoire aigu sévère (anatomopathologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Valeur prédictive des tests, Virologie (), Virulence, Virus du SRAS (isolement et purification), Virus du SRAS (pathogénicité).
- MESH :
- anatomopathologie : Appareil respiratoire, Infections à coronavirus, Syndrome respiratoire aigu sévère.
- immunologie : Appareil respiratoire, Coronavirus, Infections à coronavirus.
- isolement et purification : Coronavirus, Coronavirus du syndrome respiratoire du Moyen-Orient, Virus du SRAS.
- pathogénicité : Coronavirus, Coronavirus du syndrome respiratoire du Moyen-Orient, Virus du SRAS.
- traitement médicamenteux : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux.
- virologie : Appareil respiratoire, Infections à coronavirus, Syndrome respiratoire aigu sévère.
- Anatomopathologie moléculaire, Animaux, Appareil respiratoire, Biopsie, Coronavirus, Facteurs de risque, Humains, Immunité innée, Interactions hôte-pathogène, Maladies transmissibles émergentes, Valeur prédictive des tests, Virologie, Virulence.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (therapeutic use), Biopsy, Communicable Diseases, Emerging, Coronavirus (drug effects), Coronavirus (immunology), Coronavirus (isolation & purification), Coronavirus (pathogenicity), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (pathology), Coronavirus Infections (virology), Host-Pathogen Interactions, Humans, Immunity, Innate, Middle East Respiratory Syndrome Coronavirus (isolation & purification), Middle East Respiratory Syndrome Coronavirus (pathogenicity), Pathology, Molecular (methods), Predictive Value of Tests, Respiratory System (drug effects), Respiratory System (immunology), Respiratory System (pathology), Respiratory System (virology), Risk Factors, SARS Virus (isolation & purification), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (virology), Virology (methods), Virulence.
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug effects : Coronavirus, Respiratory System.
- drug therapy : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- immunology : Coronavirus, Coronavirus Infections, Respiratory System.
- isolation & purification : Coronavirus, Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- methods : Pathology, Molecular, Virology.
- pathogenicity : Coronavirus, Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- pathology : Coronavirus Infections, Respiratory System, Severe Acute Respiratory Syndrome.
- virology : Coronavirus Infections, Respiratory System, Severe Acute Respiratory Syndrome.
- Animals, Biopsy, Communicable Diseases, Emerging, Host-Pathogen Interactions, Humans, Immunity, Innate, Predictive Value of Tests, Risk Factors, Virulence.
Abstract
Respiratory viruses can cause a wide spectrum of pulmonary diseases, ranging from mild, upper respiratory tract infections to severe and life‐threatening lower respiratory tract infections, including the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Viral clearance and subsequent recovery from infection require activation of an effective host immune response; however, many immune effector cells may also cause injury to host tissues. Severe acute respiratory syndrome (SARS) coronavirus and Middle East respiratory syndrome (MERS) coronavirus cause severe infection of the lower respiratory tract, with 10% and 35% overall mortality rates, respectively; however, >50% mortality rates are seen in the aged and immunosuppressed populations. While these viruses are susceptible to interferon treatment in vitro, they both encode numerous genes that allow for successful evasion of the host immune system until after high virus titres have been achieved. In this review, we discuss the importance of the innate immune response and the development of lung pathology following human coronavirus infection. © 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Url:
- https://api.istex.fr/ark:/67375/WNG-ZXMDQVLL-L/fulltext.pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267971
DOI: 10.1002/path.4454
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000054
- to stream Istex, to step Curation: 000054
- to stream Istex, to step Checkpoint: 000112
- to stream Pmc, to step Corpus: 000E77
- to stream Pmc, to step Curation: 000E77
- to stream Pmc, to step Checkpoint: 001006
- to stream PubMed, to step Corpus: 001835
- to stream PubMed, to step Curation: 001835
- to stream PubMed, to step Checkpoint: 001424
- to stream Ncbi, to step Merge: 000F13
- to stream Ncbi, to step Curation: 000F13
- to stream Ncbi, to step Checkpoint: 000F13
- to stream Main, to step Merge: 001973
- to stream Main, to step Curation: 001968
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular pathology of emerging coronavirus infections</title><author><name sortKey="Gralinski, Lisa E" sort="Gralinski, Lisa E" uniqKey="Gralinski L" first="Lisa E" last="Gralinski">Lisa E. Gralinski</name></author><author><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EC2D3140AE38AD33FDB2F751563138FD7F2BE310</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/path.4454</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-ZXMDQVLL-L/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000054</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000054</idno><idno type="wicri:Area/Istex/Curation">000054</idno><idno type="wicri:Area/Istex/Checkpoint">000112</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000112</idno><idno type="wicri:doubleKey">0022-3417:2015:Gralinski L:molecular:pathology:of</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267971</idno><idno type="RBID">PMC:4267971</idno><idno type="wicri:Area/Pmc/Corpus">000E77</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E77</idno><idno type="wicri:Area/Pmc/Curation">000E77</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E77</idno><idno type="wicri:Area/Pmc/Checkpoint">001006</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001006</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:25270030</idno><idno type="wicri:Area/PubMed/Corpus">001835</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001835</idno><idno type="wicri:Area/PubMed/Curation">001835</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001835</idno><idno type="wicri:Area/PubMed/Checkpoint">001424</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001424</idno><idno type="wicri:Area/Ncbi/Merge">000F13</idno><idno type="wicri:Area/Ncbi/Curation">000F13</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F13</idno><idno type="wicri:doubleKey">0022-3417:2014:Gralinski L:molecular:pathology:of</idno><idno type="wicri:Area/Main/Merge">001973</idno><idno type="wicri:Area/Main/Curation">001968</idno><idno type="wicri:Area/Main/Exploration">001968</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Molecular pathology of emerging coronavirus infections</title><author><name sortKey="Gralinski, Lisa E" sort="Gralinski, Lisa E" uniqKey="Gralinski L" first="Lisa E" last="Gralinski">Lisa E. Gralinski</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, NC, Chapel Hill</wicri:regionArea><wicri:noRegion>Chapel Hill</wicri:noRegion></affiliation></author><author><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, NC</wicri:regionArea><wicri:noRegion>NC</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of North Carolina, NC, Chapel Hill</wicri:regionArea><wicri:noRegion>Chapel Hill</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Journal of Pathology</title><title level="j" type="sub">Viruses and Disease</title><title level="j" type="alt">THE JOURNAL OF PATHOLOGY</title><idno type="ISSN">0022-3417</idno><idno type="eISSN">1096-9896</idno><imprint><biblScope unit="vol">235</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="185">185</biblScope><biblScope unit="page" to="195">195</biblScope><biblScope unit="page-count">11</biblScope><publisher>John Wiley & Sons, Ltd</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2015-01">2015-01</date></imprint><idno type="ISSN">0022-3417</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3417</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Biopsy</term><term>Communicable Diseases, Emerging</term><term>Coronavirus (drug effects)</term><term>Coronavirus (immunology)</term><term>Coronavirus (isolation & purification)</term><term>Coronavirus (pathogenicity)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (pathology)</term><term>Coronavirus Infections (virology)</term><term>Host-Pathogen Interactions</term><term>Humans</term><term>Immunity, Innate</term><term>Middle East Respiratory Syndrome Coronavirus (isolation & purification)</term><term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term><term>Pathology, Molecular (methods)</term><term>Predictive Value of Tests</term><term>Respiratory System (drug effects)</term><term>Respiratory System (immunology)</term><term>Respiratory System (pathology)</term><term>Respiratory System (virology)</term><term>Risk Factors</term><term>SARS Virus (isolation & purification)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (pathology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Virology (methods)</term><term>Virulence</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anatomopathologie moléculaire ()</term><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Appareil respiratoire ()</term><term>Appareil respiratoire (anatomopathologie)</term><term>Appareil respiratoire (immunologie)</term><term>Appareil respiratoire (virologie)</term><term>Biopsie</term><term>Coronavirus ()</term><term>Coronavirus (immunologie)</term><term>Coronavirus (isolement et purification)</term><term>Coronavirus (pathogénicité)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term><term>Facteurs de risque</term><term>Humains</term><term>Immunité innée</term><term>Infections à coronavirus (anatomopathologie)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Interactions hôte-pathogène</term><term>Maladies transmissibles émergentes</term><term>Syndrome respiratoire aigu sévère (anatomopathologie)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Valeur prédictive des tests</term><term>Virologie ()</term><term>Virulence</term><term>Virus du SRAS (isolement et purification)</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Appareil respiratoire</term><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term><term>Respiratory System</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Appareil respiratoire</term><term>Coronavirus</term><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus</term><term>Coronavirus Infections</term><term>Respiratory System</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Coronavirus</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Coronavirus</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Pathology, Molecular</term><term>Virology</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Coronavirus</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Coronavirus</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term><term>Respiratory System</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Appareil respiratoire</term><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Respiratory System</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Biopsy</term><term>Communicable Diseases, Emerging</term><term>Host-Pathogen Interactions</term><term>Humans</term><term>Immunity, Innate</term><term>Predictive Value of Tests</term><term>Risk Factors</term><term>Virulence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Anatomopathologie moléculaire</term><term>Animaux</term><term>Appareil respiratoire</term><term>Biopsie</term><term>Coronavirus</term><term>Facteurs de risque</term><term>Humains</term><term>Immunité innée</term><term>Interactions hôte-pathogène</term><term>Maladies transmissibles émergentes</term><term>Valeur prédictive des tests</term><term>Virologie</term><term>Virulence</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Respiratory viruses can cause a wide spectrum of pulmonary diseases, ranging from mild, upper respiratory tract infections to severe and life‐threatening lower respiratory tract infections, including the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Viral clearance and subsequent recovery from infection require activation of an effective host immune response; however, many immune effector cells may also cause injury to host tissues. Severe acute respiratory syndrome (SARS) coronavirus and Middle East respiratory syndrome (MERS) coronavirus cause severe infection of the lower respiratory tract, with 10% and 35% overall mortality rates, respectively; however, >50% mortality rates are seen in the aged and immunosuppressed populations. While these viruses are susceptible to interferon treatment in vitro, they both encode numerous genes that allow for successful evasion of the host immune system until after high virus titres have been achieved. In this review, we discuss the importance of the innate immune response and the development of lung pathology following human coronavirus infection. © 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Gralinski, Lisa E" sort="Gralinski, Lisa E" uniqKey="Gralinski L" first="Lisa E" last="Gralinski">Lisa E. Gralinski</name></noRegion><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001968 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001968 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EC2D3140AE38AD33FDB2F751563138FD7F2BE310
|texte= Molecular pathology of emerging coronavirus infections
}}
| This area was generated with Dilib version V0.6.33. |  |